3M's $7.35 Billion Averages $61,250 to $63,913 a Plaintiff on Paper

Under the settlement 3M announced Tuesday, the company would pay $50 million in 2026 and nothing at all in 2027. The same day, its board authorized the repurchase of up to $6.0 billion of its own stock.

An authorization is not spending, and 3M tied its schedule to its other legacy settlement obligations, so read the pairing as a scale marker, not an accusation.

In 3M's announcement on Nov. 3, 2026, the company said it will make a $7.35 billion nominal commitment over nine years, $5.8 billion in present value, to settle AFFF personal injury claims for about 115,000 to 120,000 eligible plaintiffs. The $61,250 to $63,913 average per plaintiff is arithmetic, not an award.

AFFF is the firefighting foam at the center of the lawsuits, which allege harm from the PFAS in it, the "forever chemicals." The outlets we reviewed repeat the total; none says what a person gets.

Divide the $7.35 billion by 3M's own plaintiff range and the on-paper average runs from $61,250 to $63,913. In today's money, the $5.8 billion gives $48,333 to $50,435. Take the $680 million reserve out of the face value and the average falls to $55,583 to $58,000.

That last figure is a bound, not a finding: the release puts the reserve "in the overall financial commitment" for remaining and future claims but does not say how it is divided.

All of these are averages across everyone eligible, not what any person will be paid. Real awards will differ by injury and facts, not every eligible plaintiff will join, and whether fees, costs or liens reduce what reaches a claimant is not in the announcements. A plaintiff weighing $61,250 on paper against a schedule with no payments in 2027 cannot yet plan around a date.

Before the deal, the legal-advertising site Drugwatch said lawyers believed per-person amounts "could range from $75,000 to $500,000," while calling that speculative. The on-paper average sits below its bottom.

As of Wednesday morning, none of the following is public: the award schedule by injury or tier; how and by when claimants register; the participation threshold; whether fees, case costs or medical liens come out of awards; any year-by-year payment table; and the discount rate on the injury deal. 3M said further details will come in its SEC filings; the MDL docket, where many federal cases are pooled before one judge, is the other place to look.

Six injuries, and what joining requires

Baron & Budd and Douglas & London, whose Scott Summy and Michael London are court-appointed co-lead counsel, said in their announcement that the settlement "is intended to compensate six Eligible Injuries, which include kidney and testicular cancer." It does not name the other four.

The court's own list offers a clue. DuPont's quarterly report says the MDL court, before Judge Richard Gergel in South Carolina, ordered dismissal of claims lacking required evidence unless they alleged one of eight conditions: high cholesterol, pregnancy-induced hypertension, ulcerative colitis, thyroid disease, and testicular, kidney, liver or thyroid cancer. In early 2025, counsel said the first two would not be pursued.

Eight minus two leaves six, which appears to match the "six Eligible Injuries." That is an inference; neither 3M nor counsel has said so. For readers asking whether thyroid disease or ulcerative colitis qualifies, both are on the court's list, and neither is confirmed as covered.

On eligibility, 3M said the agreement addresses approximately 99% of current personal injury claims inside and outside the MDL, involving "approximately 115,000–120,000 plaintiffs eligible to participate in the resolution." Eligible to participate is not the same as paid. 3M described "payments contingent on plaintiffs joining the resolution," which implies joining is a step; what happens to someone who declines is unpublished.

The deal also has an exit. In its release's risk factors, 3M lists "whether the number of plaintiffs who participate in the settlement will meet current expectations or will fall below the level that would permit the Company to terminate the settlement (and whether the Company will elect to terminate the settlement if this occurs)." No threshold is disclosed.

For those who stay out, 3M pointed to "an anticipated MDL court order establishing evidentiary and timing requirements for plaintiffs who may seek to litigate in the future." It does not yet exist.

"We commend MDL No. 2873's leadership for achieving this favorable result for victims who are in urgent need of support to cover the mounting medical bills and other costs frequently associated with toxic PFAS exposure," said Fred Thompson, liaison counsel, and David Hoyle, who served on the plaintiffs' side of the 3M settlement negotiations, both of Motley Rice, in a joint statement quoted by Envirotec Magazine.

The science behind the price is still moving. Reuters says PFAS "have been linked to health issues including liver damage, lower birth weight, reduced antibody response to vaccines, and kidney and testicular cancer," and 3M says the deal "is not an admission of liability." Yet, according to 3M's filing, no personal injury bellwether trial has been held in this MDL. A first bellwether, or test, trial set for October 2025 would have involved kidney cancer plaintiffs; the court vacated it in August 2025, and "No new trial date has been set." Defendants' August 2026 motions to exclude expert testimony on liver and thyroid cancer remain pending.

A nine-year schedule with an empty 2027

3M published no year-by-year table, so what follows is illustration. Twenty percent of $7.35 billion is about $1.47 billion, due in the final two years. If "nine years" means 2026 through 2034, as 3M's subhead implies, those are 2033 and 2034. With $50 million in 2026 (3M did not say to whom it is paid) and nothing in 2027, about $5.83 billion would fall across 2028 to 2032, roughly $1.17 billion a year if spread evenly.

Present value is the sum in today's money, here 78.9% of face value, so the $1.55 billion gap is what waiting is worth in 3M's accounting. For the 2023 water deal the ratio was 82.4%, a $2.2 billion gap at 5.2%. 3M has not stated a rate for the injury deal.

3M said it will record a pre-tax charge of $5.8 billion in the fourth quarter of 2026, a special item in adjusted results that "does not change 3M's previously issued 2026 guidance." Per 3M's Oct. 20 earnings release, it guided before the deal to adjusted free cash flow of about $4.8 billion for 2026; its latest quarterly filing shows $4,835 million in cash at Sept. 30 and Moody's A3 and S&P BBB+ ratings, both stable. Adjusted figures exclude litigation charges, so they do not show cash left after settlement payments.

The company framed the schedule as a virtue. "The payment structure, over nine years, provides predictable cash flow with payments aligned to reflect other company obligations," 3M said. Predictable for 3M. For a claimant, an empty 2027 and a fifth of the money in the last two years predicts very little.

The buyback, in a second release, brings the total available to $7.5 billion with no closing date, counting $1.5 billion left from 2025. The $0.78 quarterly dividend is payable Friday, Dec. 11, to holders of record Friday, Nov. 13.

Bloomberg reported that 3M shares rose 1.7% in late trading in New York; the stock was up 11% for the year through Tuesday's close, in line with the S&P 500. William Brown, 3M's chairman and CEO, said, "This settlement is a significant milestone for 3M and substantially reduces litigation uncertainty."

Where the deal sits among the other PFAS settlements

"While nothing will make these innocent victims whole, this is the first defendant of many to come to the table."

Michael London, Douglas & London, court-appointed co-lead counsel for the plaintiffs

Only the first row below pays people for injuries. Every other row pays a government or a utility.

Reuters calls the water deal "a $10.3 billion settlement," but that is the discounted charge; the face value is up to $12.5 billion over 13 years. Mr. Brown placed the deal in that lineage: "Following our 2023 resolution with U.S. public water suppliers and our more recent settlement with the State of New Jersey, this is another important step in managing legacy PFAS matters."

The water deal was struck in June 2023, 41 months before this one.

Mr. London credits trial pressure for the result, yet, according to 3M's filing, no personal injury bellwether trial has been held in this MDL, and the liver and thyroid expert challenges are undecided. The price was set without a verdict. Nobody has a trial result to anchor a value.

The other defendants have not followed. DuPont says it "has never made or sold AFFF" and that most MDL actions name it "solely related to fraudulent transfer claims." As of Sept. 30, DuPont's own quarterly report counted approximately 13,700 personal injury cases filed in the MDL and said it is in discussions with a mediator. To our knowledge, no other defendant has announced a personal injury settlement as of Wednesday morning. Headline figures and received amounts differ, as Daybreak Wire's look at Sony's PlayStation settlement showed.

What the deal does not reach

About 1% of current claims sit outside it, and so do future ones. 3M's October filing counts approximately 15,250 pending cases, many with several plaintiffs.

Governments are separate. Suits on behalf of 33 states, the District of Columbia and four territories are pending in the MDL. New York's attorney general sued in July 2026 over consumer products, and the case was transferred to the MDL in October. Illinois stayed its case until December 2026, and New Hampshire has a "Spring 2029 trial ready date." Eighteen Alabama water systems that opted out of the 2023 settlement sued in April 2026. A separate firefighter turnout-gear MDL, created in August 2026, has 10 cases; the sources do not say whether the new deal covers it.

The next dated step, per case trackers, is Friday, Nov. 20, 16 days away, when proposals to select the next bellwether group, covering thyroid disease and ulcerative colitis, are due. Plaintiffs should get terms, registration steps and deadlines from their own lawyers, since none is published. 3M scheduled an investor call for 8:30 a.m. ET Wednesday and promised SEC filings, where missing terms may surface.

By the end of 2027, the schedule has paid $50 million of $7.35 billion, or 0.68%, and the terms that would tell a claimant when any of it is theirs have not been published.